Vigmed publishes prospectus concerning the rights issue
NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN
OR INTO THE UNITED STATES, CANADA, JAPAN, AUSTRALIA OR ANY OTHER JURISDICTION WHERE SUCH ACTION IS SUBJECT TO LEGAL RESTRICTIONS
The prospectus concerning Vigmed Holding AB’s (publ) (“Vigmed” or the “Company”) rights issue has been approved and registered by the Swedish Financial Supervisory Authority and is available on the Company’s website www.vigmed.com and on Remium’s website www.remium.com.
Vigmed has engaged ABG Sundal Collier as financial advisors and Mannheimer Swartling Advokatbyrå as legal advisor in connection with the rights issue.
Vigmed discloses the information in this press release pursuant to the Swedish Securities Markets Act.
The information was provided for public release on 12 November 2014 at 08:00 CET.
For further information contact:
Chairman of the board, Lennart Holm 46 70 630 8562 or CEO, Finn Ketler 46 42 600 5311, e-mail firstname.lastname@example.org
Vigmed is a Swedish medical technology company whose mission is to eliminate needlestick injuries by offering the market unique needle-protected products. Vigmed is headquartered in Helsingborg, Sweden, and has approximately 20 employees. Vigmed’s share is traded on NASDAQ OMX First North in Stockholm (ticker VIG) and has approximately 5 400 shareholders. Remium Nordic AB is the Company’s Certified Advisor.
Additional information such as company description, a video presentation and risk factors can be found on Vigmed’s website: www.vigmed.com/investor